Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial.
Saved in:
| Title: | Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial. |
|---|---|
| Authors: | Paton NI; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Infectious Diseases Translational Research Programme, National University of Singapore, Singapore, Singapore.; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom., Gurumurthy M; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Lu Q; Singapore Clinical Research Institute, Singapore, Singapore, Singapore., Leek F; Clinical Imaging Research Centre, National University of Singapore, Singapore, Singapore., Kwan P; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Koh HWL; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Molton J; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Mortera L; Quezon Institute, Quezon City, Philippines., Naval S; Lung Centre of the Philippines, Quezon City, Philippines., Bakar ZA; Institute of Respiratory Medicine, Kuala Lumpur, Malaysia., Pang YK; University of Malaya Medical Centre, Kuala Lumpur, Malaysia., Lum L; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Lim TK; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Cross GB; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Lekurwale G; Singapore Clinical Research Institute, Singapore, Singapore, Singapore., Choi H; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Au V; Institute of Cellular and Molecular Biology, Singapore, Singapore., Connolly J; Institute of Cellular and Molecular Biology, Singapore, Singapore., Hibberd M; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.; Department of Microbiology, National University of Singapore, Singapore, Singapore., Green JA; GSK, Greenford, United Kingdom. |
| Corporate Authors: | Pascolizumab Tuberculosis Trial Team |
| Source: | The Journal of infectious diseases [J Infect Dis] 2024 Sep 23; Vol. 230 (3), pp. 590-597. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1537-6613 |
|---|---|
| DOI: | 10.1093/infdis/jiae104 |
